Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors,
antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type …

Hyperglycemia or high blood sugar is one of the major pathological characteristics of
diabetes. The endothelium is the inner layer of the vascular wall and is directly exposed to …

Aim Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have
suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe−/−) mice. It remains to …

Background Vildagliptin, a DPP-4 inhibitor widely used for the treatment of type 2 diabetes
mellitus (T2DM), shows beneficial effects on endothelial function. This study aims to …

Objective: Diabetes mellitus (DM) is one of the risks linked with susceptibility of thrombosis.
We tried to inspect the effect of a novel oral antidiabetic agent, vildagliptin, in preventing …

Due to the progressive nature of type 2 diabetes, many patients need insulin as add-on to
oral antidiabetic drugs (OADs) in order to maintain adequate glycemic control. Insulin …

Blood pressure and lipid profile are important determinants of cardiovascular risk in patients
with type 2 diabetes mellitus (T2DM). To identify the pleiotropic effects of vildagliptin other …

Glucagon-like peptide-1 (GLP-1), a gut hormone secreted from L cells in the intestine in
response to food intake, not only augments glucosedependent insulin secretion from …

Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2
diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on …

Endothelial dysfunction is an early step to the progression of cardiovascular diseases in
diabetes. Apart from their anti-diabetic action, DPP-4 (dipeptidyl peptidase-4) inhibitors also …